Brigitte Sigal‐Zafrani

7.2k total citations · 1 hit paper
110 papers, 4.5k citations indexed

About

Brigitte Sigal‐Zafrani is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Brigitte Sigal‐Zafrani has authored 110 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Cancer Research, 60 papers in Oncology and 35 papers in Pathology and Forensic Medicine. Recurrent topics in Brigitte Sigal‐Zafrani's work include Breast Cancer Treatment Studies (58 papers), Breast Lesions and Carcinomas (31 papers) and HER2/EGFR in Cancer Research (24 papers). Brigitte Sigal‐Zafrani is often cited by papers focused on Breast Cancer Treatment Studies (58 papers), Breast Lesions and Carcinomas (31 papers) and HER2/EGFR in Cancer Research (24 papers). Brigitte Sigal‐Zafrani collaborates with scholars based in France, United States and Mali. Brigitte Sigal‐Zafrani's co-authors include Anne Vincent‐Salomon, Xavier Sastre‐Garau, Alain Fourquet, Rémy Salmon, Marc A. Bollet, Dominique Stoppa‐Lyonnet, Jean‐Yves Pierga, Youlia Kirova, Olivier Delattre and Alexia Savignoni and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Brigitte Sigal‐Zafrani

107 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Breast Lesions: Quantitative Elastography with Supersonic Shear Imaging—Preliminary Results

2010 423 citations A. Tardivon, Brigitte Sigal‐Zafrani et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brigitte Sigal‐Zafrani France	36	2.3k	2.2k	1.1k	1.0k	680	110	4.5k
Takayuki Kinoshita Japan	34	1.9k 0.8×	2.1k 0.9×	1.1k 1.0×	900 0.9×	655 1.0×	174	4.2k
Futoshi Akiyama Japan	41	2.5k 1.1×	2.7k 1.2×	2.1k 1.9×	1.7k 1.6×	832 1.2×	251	6.1k
Rohit Bhargava United States	41	2.8k 1.2×	2.4k 1.1×	1.1k 1.0×	1.6k 1.5×	565 0.8×	171	5.5k
Carolien H. M. van Deurzen Netherlands	32	1.3k 0.6×	1.6k 0.7×	1.0k 0.9×	671 0.6×	415 0.6×	108	3.3k
Rastko Golouh Slovenia	32	2.0k 0.9×	1.7k 0.7×	719 0.6×	1.1k 1.0×	488 0.7×	79	3.8k
Joon Jeong South Korea	33	1.9k 0.8×	1.7k 0.8×	573 0.5×	1.1k 1.0×	514 0.8×	274	4.0k
Isabel T. Rubio Spain	32	1.8k 0.8×	2.9k 1.3×	1.8k 1.6×	573 0.5×	563 0.8×	132	4.5k
Frances P. O’Malley Canada	43	3.1k 1.4×	2.7k 1.2×	1.6k 1.4×	2.1k 2.0×	967 1.4×	94	6.5k
Takashi Fukutomi Japan	28	1.2k 0.5×	1.2k 0.5×	813 0.7×	883 0.8×	444 0.7×	163	3.1k
Hadi Yaziji United States	27	1.8k 0.8×	680 0.3×	703 0.6×	1.1k 1.1×	878 1.3×	42	3.5k

Countries citing papers authored by Brigitte Sigal‐Zafrani

Since Specialization

Citations

This map shows the geographic impact of Brigitte Sigal‐Zafrani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brigitte Sigal‐Zafrani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brigitte Sigal‐Zafrani more than expected).

Fields of papers citing papers by Brigitte Sigal‐Zafrani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brigitte Sigal‐Zafrani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brigitte Sigal‐Zafrani. The network helps show where Brigitte Sigal‐Zafrani may publish in the future.

Co-authorship network of co-authors of Brigitte Sigal‐Zafrani

This figure shows the co-authorship network connecting the top 25 collaborators of Brigitte Sigal‐Zafrani. A scholar is included among the top collaborators of Brigitte Sigal‐Zafrani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brigitte Sigal‐Zafrani. Brigitte Sigal‐Zafrani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bonsang‐Kitzis, Hélène, Eugénie Guillot, Jean-Guillaume Féron, et al.. (2017). Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers. PLoS ONE. 12(2). e0169962–e0169962. 4 indexed citations

Massonnet, Gérald, David Gentien, Zofia Maciorowski, et al.. (2016). Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization. PLoS ONE. 11(7). e0157670–e0157670. 9 indexed citations

Ghirelli, Cristina, Fabien Reyal, Marine Jeanmougin, et al.. (2015). Breast Cancer Cell–Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes. Cancer Research. 75(14). 2775–2787. 46 indexed citations

Manié, Élodie, Tatiana Popova, Aude Battistella, et al.. (2015). Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas. International Journal of Cancer. 138(4). 891–900. 51 indexed citations

Daveau, C., Sonia Baulies, Marc A. Bollet, et al.. (2014). Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma. British Journal of Cancer. 110(9). 2195–2200. 16 indexed citations

Moarii, Matahi, Brigitte Sigal‐Zafrani, Alain Fourquet, et al.. (2014). Epigenomic Alterations in Breast Carcinoma from Primary Tumor to Locoregional Recurrences. PLoS ONE. 9(8). e103986–e103986. 6 indexed citations

Valet, Fabien, Patricia de Crémoux, F. Spyratos, et al.. (2013). Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: Experience of the REMAGUS 02 phase II trial. The Breast. 22(6). 1052–1059. 11 indexed citations

Popova, Tatiana, Élodie Manié, Guillaume Rieunier, et al.. (2012). Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation. Cancer Research. 72(21). 5454–5462. 418 indexed citations

Servant, Nicolas, Marc A. Bollet, Hans Halfwerk, et al.. (2012). Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women. Clinical Cancer Research. 18(6). 1704–1715. 55 indexed citations

10.

This, Pascale, Anne de la Rochefordière, Alexia Savignoni, et al.. (2012). Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome. Familial Cancer. 11(3). 473–482. 13 indexed citations

11.

Vincent‐Salomon, Anne, Carlo Lucchesi, Nadège Gruel, et al.. (2008). Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast. Clinical Cancer Research. 14(7). 1956–1965. 114 indexed citations

12.

Bidard, François‐Clément, Anne Vincent‐Salomon, Brigitte Sigal‐Zafrani, et al.. (2008). Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Annals of Oncology. 19(3). 496–500. 99 indexed citations

13.

Vincent‐Salomon, Anne, J-Y Pierga, J Couturier, et al.. (2007). HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?. British Journal of Cancer. 96(4). 654–659. 46 indexed citations

14.

Vincent‐Salomon, Anne, Nadège Gruel, Carlo Lucchesi, et al.. (2007). Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Research. 9(2). R24–R24. 133 indexed citations

15.

Vincent‐Salomon, Anne, Chantal Gautier, Brigitte Sigal‐Zafrani, et al.. (2005). Neoadjuvant chemotherapy for invasive lobular carcinomas of the breast: a poorer response rate but not a worse prognosis than invasive ductal carcinoma. Breast Cancer Research and Treatment. 94. 9 indexed citations

16.

Crémoux, Patricia de, Véronique Dièras, Marie‐France Poupon, et al.. (2004). [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].. PubMed. 91(12). 917–27. 8 indexed citations

17.

Nos, Claude, et al.. (2004). Breast-conserving therapy for breast cancer. Cancer/Radiothérapie. 21–28. 2 indexed citations

18.

Sastre‐Garau, Xavier, Pierre Génin, Antoine Rousseau, et al.. (2004). Increased cell size and Akt activation in HER‐2/neu‐overexpressing invasive ductal carcinoma of the breast. Histopathology. 45(2). 142–147. 14 indexed citations

19.

Stoppa‐Lyonnet, Dominique, et al.. (2004). Risk of breast recurrence in relation to BRCA1/2 mutation status following breast-conserving surgery and radiotherapy. European Journal of Cancer Supplements. 2(3). 150–151. 1 indexed citations

20.

Rosty, Christophe, et al.. (2003). Overexpression/Amplification of HER-2/neu is Uncommon in Invasive Carcinoma of the Uterine Cervix. International Journal of Gynecological Pathology. 23(1). 13–17. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact